Loading company
$2.74+1.3%Nov 13 close
Next earnings: November 19, 2026 · before the open
Figures through March 31, 2026, from the 6-K filed May 7, 2026
Past performance
- 1W
- -8.8%
- 1M
- -2.3%
- 3M
- -18.1%
- 6M
- -33.6%
- 1Y
- -49.9%
- 5Y
- -99.1%
$2.74+1.3%Nov 13 close
Next earnings: November 19, 2026 · before the open
Figures through March 31, 2026, from the 6-K filed May 7, 2026
Evaxion A/S is scheduled to report next on November 19, 2026, before the open. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending March 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2026 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $122K | -100.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases. With AI-Immunology we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Evaxion A/S filed on August 20, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Evaxion A/S has no earnings call transcript available.